



CORPORATE
SOCIAL
RESPONSIBILITY

PARTNERING TO PROMOTE ACCESS TO HEALTHCARE

CSR Brochure 2014-15




OUR RESPONSIBILITY

Ensuring healthcare for all is one of the most pressing challenges facing society today. As a global leader in healthcare, we want to use our expertise and resources to improve access to healthcare for people in need around the world.

CSR is embedded into Sanofi's core business strategy, focused on the patient at the center of our activity. Today the notion of integrated care is increasingly central to our business.

We are developing new ways to protect the health and improve the quality of life of patients everywhere, and we are committed to finding solutions for the many other CSR challenges we face.

In addition to Patient, our CSR strategy has three pillars: Ethics, People, and Planet.



Our Corporate Social Responsibility strategy is the natural outcome of our engagement to our stakeholders. The foundation on which we build our strategy is respect for human rights in all our activities.

We are committed to following this approach because we are convinced that the principles of human rights apply to people, to nations, and, by extension, to businesses.

In particular, we support each person's fundamental human right to health, through daily initiatives to improve access to healthcare for patients everywhere.

HUMAN RIGHTS GUIDE

Sanofi's in-house guide "Human Rights in our Activities" was published in 2013 to show how human rights are integrated into every aspect of our business, including the conduct of clinical trials.

Respect for human rights in drug development and research requires ensuring that all research participants have provided genuine, individual informed consent, and that their fundamental rights, such as the right to information on benefits and risks prior to giving consent, are respected and protected.



Read the guide at:

 csr.sanofi.com/downloadcenter

“ I believe that “partnership” is the most important word in advancing CSR. By putting the right people around the table, the impact that each stakeholder can have is amplified. For instance, our unique approach to improving access to healthcare is that we do not simply donate treatments. We work with our partners to assess the needs and develop programs that meet those needs.”

Christopher Viehbacher Chief Executive Officer, Sanofi

SANOFI AT A GLANCE



csr.sanofi.com

Read the full report and find out more about our CSR approach and performance.

EXTERNAL RECOGNITION FOR OUR CSR PERFORMANCE

MEMBER OF
Dow Jones Sustainability Indices
In Collaboration with RobecoSAM

ROBECOSAM
Sustainability Award
Silver Class 2014

NYSE Euronext
vigeo
EUROPE 120

access to medicine index

CDP
CLIMATE DISCLOSURE LEADER 2013

*€32,951 million

PATIENT

We are committed to working in partnership with relevant stakeholders to increase access to healthcare and quality medicines. We also improve people's health, within an economically sustainable framework that guarantees future innovation.

Ensuring patient safety is the primary focus of our quality and pharmacovigilance teams. Our approach involves guaranteeing quality at each phase of a product's life cycle, from the earliest steps of development to the distribution of products to sales channels.


KIDS PROGRAM IN INDIA

The Kids and Diabetes in Schools (KIDS) project is coordinated by the International Diabetes Federation (IDF) in partnership with the Public Health Foundation India, and Health Related Information Dissemination Amongst Youth, and sponsored by Sanofi.

For children with Type 1 diabetes, KIDS aims to foster a safe and supportive school environment to manage their diabetes and fight discrimination. It also teaches children about healthy eating habits and the importance of exercise, to curb the increasing burden of Type 2 diabetes.

SANOFI PATIENT CONNECTION

In developed countries, patients may have difficulties accessing medical treatment due to inadequate healthcare coverage and financial barriers. In order to meet patients' needs more effectively, Sanofi U.S. launched, in 2012, an integrated patient support program called Sanofi Patient Connection™. It assists patients and healthcare professionals with a wide variety of services across the U.S. product portfolio including biosurgery, cardiovascular, diabetes, general therapeutics, oncology, specialty care, transplant, and vaccines. In 2013, the Sanofi Patient Connection assisted **over 210,000 patients** and supported over **54,000 healthcare providers**.



We seek to improve the lives of people everywhere by expanding access to healthcare and developing innovative solutions that meet patients' needs.

More than 260 access to healthcare programs in more than 70 countries worldwide

177 MILLION
people benefited,
including:

79 MILLION
people targeted by
awareness campaigns

98 MILLION
patients received
diagnosis, vaccination,
treatment, or disease self-
management training

163,000
healthcare
professionals trained

TIER PRICING PROGRAM AGAINST MALARIA

Even when patients have access to adequate healthcare, financial barriers can create a substantial obstacle to maintaining health and preventing diseases. A large proportion of patients worldwide face an economic burden stemming from the direct and indirect costs of healthcare. Ensuring affordable treatment provisions is key to expanding access to medicines. Thanks to our tiered pricing and our anti-malarial drug Coarsucam/Artesunate-Artesunate (Winthrop®) is made available in malaria endemic countries. In 2013, ASAQ were sold in 2013, using a preferential pricing model (compared to 73 million units in 2012 and 50 million units in 2011).



ETHICS

We are committed to conducting clinical trials worldwide by applying the most stringent quality standards and making a particular effort to protect trial subjects who may be vulnerable for any reason.

Sanofi has a responsibility to behave with integrity and transparency, to respect the highest ethical standards in all our business dealings. We apply CSR principles in our procurement activities by selecting goods and services that are produced and provided in compliance with demanding environmental, social, and ethical standards.

BIOETHICS COMMITTEE

The Sanofi Bioethics Committee, which was created in 2010, studies emerging ethical issues brought about by advances in biology and medicine. The Committee develops our positions on bioethics, which are one of the components of our research strategy. In 2013 the Sanofi Bioethics Committee launched an initiative to make our clinical study documents more consistent, and produce materials and processes that are easier for potential participants to understand. The Committee drew up **11 key factors** to improve the informed consent process, focused on the difference between study participation and medical care, alternatives to study participation, and trial participants' access to the tested medicine or vaccine.

CODE OF ETHICS

Our Code of Ethics provides clear guidelines on how the company expects employees to behave when conducting Sanofi business. It is provided as a resource to help employees in dealing with issues that they may encounter as part of their day-to-day functional responsibilities, both inside and outside the Group. As of the end of 2013, **over 97,000 employees** have received training in the Sanofi Code of Ethics.

ARIA

care and medicines, cost of good health and managing disease must bear a substantial and indirect costs of illness and disease is one of the key factors in our tiered pricing policy, through which we have reduced the price of hydroxychloroquine Winthrop (ASAQ) in emerging countries, **80 million units** of hydroxychloroquine Winthrop (ASAQ) under our tiered pricing policy including no profit–no loss (1.4 million units in 2011).



Acting responsibly and ethically provides the basis for our day-to-day work, and our relations with patients, healthcare professionals, Sanofi employees, and our many other stakeholders.

PEOPLE

The men and women of Sanofi are the real drivers of our business performance, and their well-being is essential to our success.

Our multicultural workforce is a rich source of talent, innovation, and competitiveness.

We embrace diversity as an opportunity to develop creative solutions to better address the needs of patients and our other stakeholders.

ENFANTS DE SANOFI



"Enfants de Sanofi" is a non-profit association created to help employees' children from birth to the age of 25. It provides

support for children who are experiencing hardships such as health problems, difficulties in their studies, and social or family troubles.

This association provides individual support to families and also organizes collective initiatives at many Sanofi affiliates worldwide, with a focus on vaccination, dental care, vision testing, and educational programs.

A selection of key figures

3,400

children benefited from initiatives from Enfants de Sanofi

10.5%

Reduction in motor vehicle accidents compared to 2010

45%

Proportion of women in the total workforce

23.8%

Reduction in lost time injury frequency rate compared to 2010



We care about the well-being and professional development of all Sanofi employees; they are the key to our business performance.

DIVERSITY POLICY

Our global **Diversity Department**, developed the Sanofi **Diversity Policy** in 2013, which is designed to promote diversity in the broadest sense possible. It outlines the framework and principles governing non-discrimination, equal opportunity, and respect for individuals. Sanofi prohibits all forms of unlawful discrimination and complies with international standards and applicable local laws in the area of human rights and labor law.

PLANET

Reducing our carbon footprint and finding innovative ways to optimize the energy performance of all our business activities is an essential part of our responsibility to act against climate change and protect life on the planet.

We are committed to managing water responsibly to safeguard the health of individuals and communities.

Pharmaceuticals found in the environment due to human activity, such as patients' use of medicines, raise concerns about their potential impact on human health and the planet. This is a challenge that Sanofi takes seriously.

SAFE SHARPS DISPOSAL IN FRANCE

Alongside 40 other pharmaceutical companies, manufacturers, and distributors of medical devices, Sanofi has been a driving force in DASTRI, a program to help ensure the safe disposal of "sharps" (needles, lancets, infusion sets, etc.) after use by patients. Providing special sharps containers free of charge for collection and disposal, as well as improving communication and awareness among all stakeholders, DASTRI aims to collect an estimated **360 tons** of sharps from **15,000 collection points** across France.

A selection of key figures

8.7%

Reduction in energy consumption compared to 2010

14.7%

Reduction in CO₂ emissions from the transport of medicines compared to 2012

19.8%

Reduction in water consumption compared to 2010

5.2%

Reduction in CO₂ emitted by pallets transported

RECYCLING WASTEWATER IN ANKLESHWAR, INDIA

To reduce discharge from our chemistry and pharmaceutical sites at Ankleshwar in India, we invested in an on-site wastewater treatment plant. It uses cutting-edge technologies and processes to treat the site's wastewater. Today, **80 to 90%** of treated wastewater can be reused in the site's cooling towers. This project helps conserve natural resources in line with Indian regulatory requirements and a "zero discharge" target established by the local pollution-control board.



As a global healthcare leader, we live up to our responsibility to protect life on the planet by limiting the environmental impact of our activities.

FSC LOGO HERE IF
NEEDED



**CORPORATE
SOCIAL
RESPONSIBILITY**

Each day, across the globe, Sanofi's 110,000 employees are working to protect your health and improve access to healthcare for as many patients as possible. As a healthcare company, Sanofi places quality, safety, ethics, and respect for the planet at the heart of our business.



54, rue La Boétie 75008 Paris – France | Tel.: +33 (0)1 53 77 40 00
<http://csr.sanofi.com> | corporate-responsibility@sanofi.com